Showing 1–17 of 17 documents
Sorted by hybrid relevance (keyword + semantic via RRF)
Mi Zhou, Xuren Chen, Jie Huang, Runlin Su, Hongmei Lei, et al.
**BACKGROUND:** Pediatric tuberculosis (TB) management remains an underemphasized area plagued by diagnostic and treatment challenges that are compounded further due to rising levels of drug-resistant tuberculosis (DR-TB). Even though TB incidence is high in China, limited data e…
Sharma S, Sarin R, Sahu G, Shukla G
Background Pediatric tuberculosis (TB) constitutes 8% of the total caseload of TB. Children are particularly vulnerable to dissemination of disease and mortality. Aim To determine mortality rate, elucidate type of TB, causes and predictors of mortality, if any, in admitted pediat…
Shah I, Antony S, Jaiswal A, Bodhanwala M, Shah D, et al.
…ptimized background regimen including Dlm or Bdq or both in pediatric MDRFQ/SLI/XDR-TB patients who failed a standard MDR-TB regimen under the National Tuberculosis Elimination Programme in Mumbai, India. Design and methods Retrospective descriptive analysis study. National Tuber…
Wang T, Dong F, Li QJ, Yin QQ, Song WQ, et al.
…s and characteristics of drug resistance in newly diagnosed pediatric tuberculosis (TB) patients in northern China. Methods Mycobacterium tuberculosis isolates were collected from September 2010 to October 2016 at the Beijing Children's Hospital. Patients were divided into two gr…
Shah MA, Shah I
Background The prevalence and type of Drug resistant tuberculosis (DR-TB) was evaluated pre- and post-2013, and outcome was studied. Methods Descriptive retrospective study. Children were defined as having DR-TB on the basis of GeneXpert or line probe assay and/or drug susceptibi…
Khurana P, Saigal K, Ghosh A
Background The emergence of multidrug-resistant MDR-TB and extensively drug-resistant XDR-TB are serious threats to global TB control. Molecular tests like GenoType MTBDRplus has revolutionized MDR-TB diagnosis by rapid detection of resistance, leading to early and appropriate ma…
Sharma S
The WHO's End TB Strategy and the United Nations' (UN) Sustainable Development Goals (SDGs) share the common aim to end the global TB epidemic. Specific targets have been set in the End TB Strategy, for the period 2016-2035, which include a 90% reduction in TB deaths and an 80% r…
Sun J, Fan L, Zhao Y, Wu H, Li R, et al.
…We retrospectively analyzed drug resistance testing data of pediatric TB patients between 2017 and 2021, and included 2976 clinically-diagnosed pediatric TB patients. We described the epidemiology of DR-TB and analyzed the trends of DR-TB incidence. The Kappa value was calculated…
Wamaka Kaminyoge, Reuben Simfukwe, Mwiza Singini, Norman Sitali, Felix P Chilunga
…wer, all-oral bedaquiline- and delamanid-based regimens for pediatric MDR/XDR-TB are effective and generally well tolerated, though the full safety profile remains incompletely characterized. In pediatric MDR/XDR-TB, where studies are rare, our findings provide the best available…
Pecora F, Dal Canto G, Veronese P, Esposito S
… last few years. It has been estimated that about 3% of all pediatric TB is MDR, meaning about 30,000 cases each year. Although most children with MDR-TB can be successfully treated, up to five years ago effective treatment was associated with a high incidence of severe adverse e…
Song WM, Li YF, Liu YX, Liu Y, Yu CB, et al.
…ntified 4,063 studies, of which 37 were included. Of 23,652 pediatric TB patients, the proportions of DR-TB, MDR-TB, mono-resistant TB, polydrug resistant TB, extensively drug-resistant TB were 13.59% (1,964/14,453), 3.72% (881/23,652), 6.07% (529/8,719), 1.61% (119/7,361), 0.44%…
Shah I, Poojari V, Meshram H
…NTCP, the use of DLM is approved in children 6 y and above. Pediatric MDR/XDR TB treatment outcome with newer anti-TB drugs and regimen is lacking. Children when treated with individualized regimens have improved survival.
Pirmahmadzoda B, Hann K, Akopyan K, Grigoryan R, Geliukh E, et al.
Introduction Approximately 3% of all pediatric TB cases develop MDR-TB, with only 3-4% of such children receiving MDR-TB treatment. In Tajikistan, children as a proportion of all DR-TB in the country increased from 4.3 to 7.5% during 2013-2018. Despite limited evidence on the use…
Patra J, Irving H, Maini P, Liang J, Patra A, et al.
…XDR- tuberculosis (TB) account for approximately a third of pediatric MDR-TB cases globally. Clinical management is challenging; recommendations are based on limited evidence. We assessed the clinical outcomes for children and adolescents treated for XDR-and pre-XDR-TB. We perfor…
Shah I, Gandhi S, Shetty NS
Bedaquiline and delamanid used to treat extensively drug-resistant tuberculosis are known to cause prolonged QTc. Two children with extensively drug-resistant tuberculosis were put on bedaquiline and delamanid and had prolonged QTc on the Bazett formula but normal QTc by the Frid…
Shang W, Cao G, Jing W, Liu J, Liang W, et al.
Objective Tuberculosis (TB) is a major health threat in adolescents and young adults. However, its burden in this population remains unclear. This study aimed to assess TB burden and changing trends in individuals aged 10 to 24 years from 1990 to 2019. Methods All data were obtai…
Harichander S, Bangalee V, Oosthuizen F
Background Children represent a particularly vulnerable demographic in the context of drug-resistant (DR) tuberculosis (TB) due to their increased likelihood of close contact with adults diagnosed with the disease. Approximately 25 000-30 000 children develop DR-TB annually. Whil…